Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

What is the optimal therapeutic approach following progression on front line PARP inhibitor maintenance therapy in ovarian cancer?

Systemic treatment options following progression on PARPi

Date

23 Oct 2023

Session

What is the optimal therapeutic approach following progression on front line PARP inhibitor maintenance therapy in ovarian cancer?

Topics

Tumour Site

Ovarian Cancer

Presenters

Isabelle Ray-Coquard

Authors

I.L. Ray-Coquard

Author affiliations

  • Medical Oncology Department, Centre Léon Bérard, 69008 - Lyon/FR

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.